Next Article in Journal
Stem Cells Derived from Lipoma and Adipose Tissue—Similar Mesenchymal Phenotype but Different Differentiation Capacity Governed by Distinct Molecular Signature
Previous Article in Journal
Alpha-Synuclein and Calpains Disrupt SNARE-Mediated Synaptic Vesicle Fusion During Manganese Exposure in SH-SY5Y Cells
Previous Article in Special Issue
The Dual Role of TAM Receptors in Autoimmune Diseases and Cancer: An Overview
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessCommunication
Cells 2018, 7(12), 259; https://doi.org/10.3390/cells7120259

Lysosomal Sequestration Impairs the Activity of the Preclinical FGFR Inhibitor PD173074

1
Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I, Medical University of Vienna, A-1090 Vienna, Austria
2
Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, A-1090 Vienna, Austria
3
Research Cluster "Translational Cancer Therapy Research", A-1090 Vienna, Austria
4
Institute of Cell Biology, National Academy of Sciences of Ukraine, 79005 Lviv, Ukraine
*
Author to whom correspondence should be addressed.
Received: 28 September 2018 / Revised: 3 December 2018 / Accepted: 4 December 2018 / Published: 8 December 2018
(This article belongs to the Special Issue Receptor Tyrosine Kinases in Health and Disease)
Full-Text   |   PDF [9324 KB, uploaded 8 December 2018]   |  

Abstract

Knowledge of intracellular pharmacokinetics of anticancer agents is imperative for understanding drug efficacy as well as intrinsic and acquired cellular resistance mechanisms. However, the factors driving subcellular drug distribution are complex and poorly understood. Here, we describe for the first time the intrinsic fluorescence properties of the fibroblast growth factor receptor inhibitor PD1703074 as well as utilization of this physicochemical feature to investigate intracellular accumulation and compartmentalization of this compound in human lung cancer cells. Cell-free PD173074 fluorescence, intracellular accumulation and distribution were investigated using analytical chemistry and molecular biology approaches. Analyses on a subcellular scale revealed selective drug accumulation in lysosomes. Coincubation with inhibitors of lysosomal acidification strongly enhanced PD173074-mediated fibroblast growth factor receptor (FGFR) inhibition and cytotoxicity. In conclusion, intrinsic fluorescence enables analysis of molecular factors influencing intracellular pharmacokinetics of PD173074. Lysosome-alkalinizing agents might represent candidates for rational combination treatment, preventing cancer cell-intrinsic PD173074 resistance based on lysosomal trapping. View Full-Text
Keywords: cancer; drug sequestration; fibroblast growth factor receptor; fluorescence; lysosomes; TKI cancer; drug sequestration; fibroblast growth factor receptor; fluorescence; lysosomes; TKI
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Englinger, B.; Kallus, S.; Senkiv, J.; Laemmerer, A.; Moser, P.; Gabler, L.; Groza, D.; Kowol, C.R.; Heffeter, P.; Grusch, M.; Berger, W. Lysosomal Sequestration Impairs the Activity of the Preclinical FGFR Inhibitor PD173074. Cells 2018, 7, 259.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top